COMPLICATIONS HEMODYNAMIQUES
1. Larche J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G et al. Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 2003; 29(10):1688-1695.
Etude rétrospective avec 88 patients suggérant de meilleurs résultats au cours de ces dernières années.
2. Meert AP, Sculier JP. Activated protein C in daily practice. Intensive Care Med 2006 Apr;32(4):617.
Série prospective de 27 patients atteints de cancer et avec sepsis sévère: seuls 5 sont éligibles pour recevoir la protéine C activée recombinante.
3. Pene F, Percheron S, Lemiale V, Viallon V, Claessens YE, Marque S, Charpentier J, Angus DC, Cariou A, Chiche JD, Mira JP. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 36: 690-6, 2008.
Etude observationnelle rétrospective.
4.Vandijck DM, Benoit DD, Depuydt PO, Offner FC, Blot SI, Van Tilborgh AK, Nollet J, Steel E, Noens LA, Decruyenaere JM.
Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med 34: 847-55, 2008.
Etude observationnelle rétrospective.
5.Gow KW, Lao OB, Leong T, Fortenberry JD. Extracorporeal life support for adults with malignancy and respiratory or cardiac failure: The Extracorporeal Life Support experience. Am J Surg 2010 May;199(5):669-75.
Etude de registre.
6. Zuber B, Tran TC, Aegerter P, Grimaldi D, Charpentier J, Guidet B, et al. Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med 2012 Jan;40(1):55-62.
Etude rétrospective.
7. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012 Jan;40(1):43-9.
Etude rétrospective.